Physician profile
Khurram Bari
NPI 1689851677
$123,966.57
in general payments reported to CMS, 2019-2025
12 companies · $22K in 2025
The $22K reported for 2025 was more than what 84% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,534 · 2020: $115 · 2021: $2,360 · 2022: $8,203 · 2023: $35K · 2024: $47K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Travel and Lodging: $7,484 · Honoraria: $6,450 · Food and Beverage: $3,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,465.00 |
| Travel and Lodging | $7,484.26 |
| Honoraria | $6,450.00 |
| Food and Beverage | $3,355.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $98,358.03 | 2022-2025 | Terlivaz |
| Madrigal Pharmaceuticals | $11,683.17 | 2024-2025 | Rezdiffra |
| Dova Pharmaceuticals | $6,631.52 | 2019 | |
| Gilead Sciences, INC. | $2,484.94 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $2,465.38 | 2019 | |
| Kowa Research Institute, INC. | $1,465.38 | 2024 | |
| Amgen INC. | $358.16 | 2019-2025 | Uplizna |
| Abbvie INC. | $339.53 | 2019-2025 | Mavyret |
| Bard Peripheral Vascular, INC. | $83.96 | 2019 | |
| Reflow Medical INC | $75.00 | 2025 | |
| Intercept Pharmaceuticals, INC. | $21.50 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Bari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.